To compare interferon ␤-1b (IFN␤-1b) and glatiramer acetate (GA) on new lesion (NL) (gadolinium-enhancing, new T2) evolution into permanent black holes (PBH)-a marker of irreversible tissue damage-in patients with relapsing-remitting multiple sclerosis (RRMS).
sions. Cumulative gadolinium-enhancing lesion number and change in T1-hypointense lesion volume from screening to LAS, which captures all T1-hypointense lesions irrespective of age or permanence, were similar. Permanent T1-hypointense lesions, permanent black holes (PBH), are considered to be markers of irreversible brain tissue damage in multiple sclerosis (MS), [2] [3] [4] [5] [6] with a strong correlation between the degree of T1 hypointensity and percentage of residual axons. 7 Monitoring of PBH formation requires assessment of new lesion (NL) evolution over time, 4 with lesions remaining T1-hypointense for Ͼ6 -12 months considered permanent. 4, 8, 9 The BECOME study compared the ability of IFN␤-1b 250 g and GA to suppress MRI disease activity in patients with RRMS or clinically isolated syndrome using monthly imaging. 10 From month 1 to year 2, IFN␤-1b-treated patients had a significantly lower proportion of NL that became PBH than GAtreated patients. 11 On the basis of hypotheses generated in BECOME, patient scans from BEYOND were reanalyzed to assess PBH evolution at year 2 from NL at year 1.
METHODS Standard protocol approvals, registrations, and patient consents. BEYOND (NCT00099502) was done according to good clinical practice and the Interna-tional Conference on Harmonization guidelines. The institutional review boards of all participating centers approved the study protocol, and patients provided written informed consent before entering into the trial.
Patients. BEYOND was a large (n ϭ 2,244), phase III, prospective, multicenter, randomized, parallel-group, blinded clinical study of treatment-naive patients with RRMS and baseline Expanded Disability Status Scale (EDSS) scores between 0 and 5 (table e-1 on the Neurology ® Web site at www.neurology.org). Patients were randomized (2:2:1) to receive IFN␤-1b 250 g subcutaneously every other day, IFN␤-1b 500 g subcutaneously every other day, or GA 20 mg subcutaneously daily for a minimum of 2 years and up to 3.5 years. MRI scans were acquired at baseline and annually thereafter. The primary results have been published. 1 All available MRI scans were reanalyzed post hoc to the BEYOND trial in a blinded manner by the Neuroimaging Research Unit in Milan, Italy. The image acquisition protocol is described elsewhere. 1 To qualify, patients had to have NL information at year 1 and lesion follow-up at year 2. Using year 1 scans as the baseline allowed the assessment of only those lesions that formed while on treatment. NL included gadolinium-enhancing and new T2 lesions with or without associated black holes at year 1. A new T2 lesion was defined as an area of hyperintensity on dual-echo scans at year 1 arising from an area of previously normal-appearing white matter on baseline scans. PBH were defined as those lesions with signal intensity between that of gray matter and CSF on postcontrast T1weighted images. Year 3 scans were not reanalyzed as only approximately one-quarter of patients (23.4%, 312/1,333) were followed until this time point.
Statistical analyses.
Patient scans were reexamined for PBH post hoc to the BEYOND trial in a rater-blinded manner. The 2 predefined coprimary endpoints compared IFN␤-1b 250 g with GA via conditional, sequential testing: first, the number of PBH per patient at year 2 that evolved from NL present at year 1 was analyzed; if significant, then the proportion of NL at year 1 that became PBH at year 2 was assessed. p Values less than 0.05 were considered significant. Conditional, sequential testing allowed for control of the type I error. IFN␤-1b 500 g was also compared with GA on the 2 coprimary endpoints in an exploratory fashion.
Lesion counts were analyzed by negative binomial regression (without consideration of the presence of gadolinium-enhancing lesions at screening) and patient-and lesion-based proportions by logistic regression. Statistical analyses comparing the proportion of NL at year 1 that evolved into PBH at year 2 were adjusted for intrapatient correlations using generalized estimating equations (GEE). Sensitivity analyses that stratified by NL type (i.e., gadolinium-enhancing lesions, new T2 lesions associated with black holes at year 1, and new T2 lesions not associated with black holes at year 1) were performed, with nominal p values reported. In additional lesion-based analyses, year 1 NL volume (categorized into quartiles) or location (discrete, periventricular, posterior fossa, juxtacortical) was considered as a covariate (GEE analysis adjusted for intrapatient lesion correlation), and number of PBH per patient at year 2 evolving from year 1 NL was analyzed considering baseline T1-hypointense lesion volume (categorized according to median value), gender, and baseline EDSS score (Ͻ3, Ն3) as covariates (negative binomial regression). All analyses were performed using SAS statistical software package version 9.1. clinical and MRI measures of disease at baseline were similar among the treatment arms (table 1) . Of 1,957 patients, the proportions of patients in each treatment arm with at least one gadolinium-enhancing lesion at year 1 were as follows: IFN␤-1b 500 g, 12.9% (99/ 767); IFN␤-1b 250 g, 14.2% (113/797); and GA, 17.8% (70/393). The proportions of patients with at least one new T2 lesion at year 1 were as follows:
RESULTS
IFN␤-1b 500 g, 30.1% (231/767); IFN␤-1b 250 g, 31.0% (247/797); and GA, 41.7% (164/393).
Number of PBH at year 2 that evolved from NL at year
1. For the first coprimary endpoint, individuals treated with IFN␤-1b 250 g had a lower mean number of PBH per patient at year 2 that evolved from NL at year 1 compared with GA-treated patients (0.30 vs 0.43; p ϭ 0.0451). A reduced number of PBH at year 2 that evolved from NL at year 1 was observed when comparing IFN␤-1b 500 g with GA (0.26 vs 0.43; p ϭ 0.0037) (figure 2). These differences correspond to a relative risk reduction of 30% for IFN␤-1b 250 g and 40% for IFN␤-1b 500 g relative to GA.
Proportion of NL at year 1 that became PBH at year 2.
Among IFN␤-1b 250 g-treated patients, doses than GA (IFN␤-1b 250 g vs GA, p ϭ 0.0856; IFN␤-1b 500 g vs GA, p ϭ 0.0038). Consistent patterns by treatment arms were observed when adjusting for gender (IFN␤-1b 250 g vs GA, p ϭ 0.0741; IFN␤-1b 500 g vs GA, p ϭ 0.0065), with more pronounced effects among men (IFN␤-1b 250 g vs GA, 0.31 vs 0.68; p ϭ 0.0062; IFN␤-1b 500 g vs GA, 0.36 vs 0.68; p ϭ 0.0198) than women (IFN␤-1b 250 g vs GA, 0.30 vs 0.32; p ϭ 0.8006; IFN␤-1b 500 g vs GA, 0.21 vs 0.32; p ϭ 0.0903). After adjusting for baseline EDSS, findings on the numbers of PBH per patient (IFN␤-1b 250 g vs GA, p ϭ 0.0463; IFN␤-1b 500 g vs GA, p ϭ 0.0027) were consistent with the primary outcome analysis, with potentially more pronounced effects among patients with baseline EDSS scores Ն3 (IFN␤-1b 250 g vs GA, 0.27 vs 0.55; p ϭ 0.0238; IFN␤-1b 500 g vs GA, 0.21 vs 0.55; p ϭ 0.0031) than Ͻ3 (IFN␤-1b 250 g vs GA, 0.32 vs 0.38; p ϭ 0.4074; IFN␤-1b 500 g vs GA, 0.28 vs 0.38; p ϭ 0.1194).
As year 1 served as the baseline measurement in this analysis, the potential influence of year 1 NL location (discrete, periventricular, posterior fossa, juxtacortical) and volume on the proportion of PBH at year 2 was also assessed. Neither adjustment for location (IFN␤-1b 250 g vs GA, p ϭ 0.5861; IFN␤-1b 500 g vs GA, p ϭ 0.0471) nor for categorized lesion volume (IFN␤-1b 250 g vs GA, p ϭ 0.5310; IFN␤-1b 500 g vs GA, p ϭ 0.1316) altered the overall results. While categorized NL volume did not influence the treatment effects on PBH evolution, there was a potentially marginal contribution of the IFN␤-1b 500 g dose on very large lesions (i.e., Ն185. DISCUSSION Assessment into the evolution of NL into PBH allows for monitoring of brain tissue destruction 4, 12, 13 and may be used as a biomarker for neuroprotection. 6 MRI evidence supporting a neuroprotective role for GA stems from the reduction in the number of NL that evolved into PBH relative to placebo. 4 Similar results have been reported for natalizumab. 14 In addition, the proportion of PBH that evolved from NL over 3 years of IFN␤-1b use was lower than that in the 3 years before treatment initiation. 15 The BECOME study, which compared IFN␤-1b 250 g with GA, revealed that a lower proportion of NL evolved into PBH in IFN␤-1btreated than in GA-treated patients. 10 This outcome served as the basis for the hypotheses tested in this analysis.
In this PBH analysis of the BEYOND study, the first coprimary endpoint-the number of PBH per patient at year 2 that evolved from NL at year 1-reflects the net number of such lesions that formed while patients were on treatment and can be considered a measure of the overall extent of irreversible tissue damage occurring under treatment. The mean numbers of PBH per patient at year 2 that evolved from NL present at year 1 were lower for both doses of IFN␤-1b than GA. The second coprimary endpoint, the proportion of NL converting into PBH, provides insight into the developmental fate of lesions that occur on treatment. While the proportion of NL at year 1 that evolved into PBH at year 2 was similar between IFN␤-1b 250 g and GA, treatment with IFN␤-1b 500 g resulted in fewer NL that became PBH than GA.
As the original BEYOND study design used infrequent, annual MRI scans, acute NL presence at year 1 served as the gating measurement of new, ontreatment disease activity. This analysis excluded baseline lesions because such lesions would not yet have been influenced by treatment during their subacute evolution. In this study, NL included both gadolinium-enhancing and new T2 lesions. Though only infrequent MRI scans were available from the BEYOND dataset, studies with frequent imaging have established that T2 lesions evolve from gadolinium-enhancing lesions in more than 95% of instances. 4, 11, 16 This thus permits use of new T2 lesions as a marker of cumulative NL activity. To examine PBH origin by NL type, sensitivity analyses were performed. These analyses indicated that the observed differences between IFN␤-1b 250 g and GA for the 2 coprimary endpoints were mostly attributable to PBH at year 2 evolving from new T2 lesions at year 1, and to a lesser degree to gadoliniumenhancing lesions. This is likely due to the frequency of scanning: gadolinium-enhancing lesions are tran- sient with the vast majority inevitably lost when performing annual scans, but new T2 lesions can be seen on the last scan independently of the time of their formation during the interval between 2 consecutive scans. Adjusting for the covariates NL location, NL volume, baseline EDSS, and gender suggested that men and patients with higher baseline EDSS scores or higher lesion volume may in part contribute to the formation of a greater number of PBH. However, these adjustments did not alter the interpretation of the overall analysis.
The previous BEYOND MRI analysis on the change in volume of all T1 hypointensities showed no differences between the treatment groups. 1 The partial differences between the primary BEYOND MRI analysis and this lesion-based assessment may be explained by the following: first, the primary MRI analysis measured T1-hypointense lesion volume change from screening to last available scan, while the post hoc analysis examined individual lesion evolution. Second, this post hoc analysis used only those lesions that formed while patients were on treatment. This controlled for the variable time diseasemodifying therapies may need to exert their effects. 17 Third, unlike the previous analysis, the design of this analysis distinguishes between acute and permanent T1 hypointensities. Fourth, new black holes that develop on treatment represent only a very small proportion of the overall burden of existing T1hypointense lesions found at baseline, 1 likely reducing the sensitivity of this measure.
The primary analysis of the BEYOND study also examined another potential marker of permanent tissue destruction, whole brain volume. No differences were found among the treatment arms for the change in brain volume from screening to LAS. However, from screening to year 1, patients treated with either IFN␤-1b dose experienced greater decreases in brain volume than did those assigned to GA. This effect was not seen from years 1 to 2 or from years 2 to 3, 1 suggesting that IFN␤-1b may have more pronounced effects on whole brain inflammation soon after treatment initiation than GA. As with the change in T1-hypointense lesion volume from screening to LAS, whole brain volume is a coarse measurement. We believe that lesion-by-lesion analyses, such as those reported here, provide greater sensitivity and insight into the effects of diseasemodifying treatments on MS course.
While its precise mechanism of action remains unknown, IFN␤-1b may indirectly promote neuronal preservation by altering lesion destructiveness through a downregulation of matrix metalloproteinases, which are known to degrade extracellular matrices. 18 Second, relative to healthy controls, immune cells harvested from patients with RRMS secrete reduced levels of brain-derived neurotrophic factor (BDNF), a protein that prevents neuronal cell death and promotes remyelination. 19 Treatment with IFN␤ has been shown to upregulate expression of BDNF. 20, 21 Also, nerve growth factor is induced in a dose-dependent manner by IFN␤ 22 and is inversely correlated to MRI measures of axonal loss. 23 Third, IFN␤-1b induces the expression of proteins associated with the inhibition of oxidative stress. [24] [25] [26] These potential pleiotropic effects may allow IFN␤-1b to confer neuroprotection via a variety of synergistic mechanisms.
The reasons for the different effects of the 2 IFN␤-1b doses on the proportion of NL that evolved into PBH at year 2 remain to be established. Two potential, not necessarily mutually exclusive, explanations might be considered. Either there is a dose response, meaning the higher, experimental dose (IFN␤-1b 500 g) is more neuroprotective than IFN␤-1b 250 g, or the extent of destructiveness of the lesions that have already formed is systematically reduced by a more anti-inflammatory effect exerted by IFN␤-1b 500 g relative to IFN␤-1b 250 g. However, in the absence of MRI sequences with an increased specificity toward the most destructive aspects of MS pathology (i.e., irreversible demyelination and axonal loss) and of a more frequent MRI scanning schedule (e.g., monthly, as was the case for BECOME), it is not possible to determine on which aspect of lesion evolution-formation or resolution-IFN␤-1b 500 g is exerting its effects.
This study was not without limitations. First, it was based on a post hoc reanalysis of MRI scans obtained from the BEYOND study. Second, it was methodologically limited by the neutral outcomes on the primary and secondary endpoints of the BEYOND study. 1 Third, our dataset captured only infrequent MRI time points, thus allowing for only a partial assessment of lesion evolution and limiting our ability to define the actual time when PBH occurred. Despite these limitations, we believe in the internal validity of our data, since we achieved high ascertainment of a large study population, with resulting treatment cohorts that were well-matched on both disease and demographic characteristics. Furthermore, the proportion of NL that developed into PBH was similar to that measured in other studies. 4, 10 Sensitivity and covariate analyses did not alter the overall interpretation. Finally, the outcomes achieved upon comparison of IFN␤-1b 250 g with GA were corroborated by the IFN␤-1b 500 g dataset. Overall, these data show that IFN␤-1b 250 g favorably influences an MRI outcome indicative of permanent tissue destruction in the brains of patients with MS-to at least a similar degree as GA. The more pronounced effect of the higher, experimental dose is intriguing, and warrants further investigation into its potential mechanisms of action. dustries Ltd.; has served on independent data and safety monitoring committees for Antisense Therapeutics Limited, Sanofi-Aventis, Bayhill Pharmaceuticals, BioMS Medical Corp, Daiichi-Sankyo Co. Inc., Glaxo-SmithKline, Genmab A/S, Medivation Inc., PTC Therapeutics Inc., Teva Pharmaceutical Industries Ltd., Vivus Inc., NHLBI, NINDS, NMSS; has
